Cancer-related cognitive impairment (CRCI) is a long-term decline in thinking abilities that can happen after cancer or its ...

About two thirds of breast cancers are classified as “hormone receptor positive” disease. These cancer cells express a group of proteins that bind to hormones, including estrogen and progesterone, ...

More than 40% of Americans with estrogen receptor (ER)-low early breast cancer did not receive endocrine therapy, analysis of a national database showed. Omitting endocrine therapy in ER-low breast ...

Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that Itovebi® (inavolisib) is the first breast cancer therapy ...

Researchers examined whether CDK4/6 inhibitors lead to better overall survival when used as first- or second-line treatment.

Denosumab monotherapy versus bisphosphonate switching in breast cancer bone metastases: A real-world cohort study on skeletal events and safety. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Researchers explored the link between medication adherence and symptom distress in patients with breast cancer undergoing endocrine therapy.

New data presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) from the NRG/NSABP B-42 trial demonstrated that the Endocrine Activity Index (EAI) identifies postmenopausal women with ...

A novel artificial intelligence (AI) application capable of diagnosing endocrine cancers with speed and accuracy is being presented Sunday at ENDO 2025, the Endocrine Society's annual meeting in San ...

Verzenio plus endocrine therapy reduced death risk by 15.8% in high-risk early breast cancer patients compared to endocrine therapy alone. The monarchE trial showed improved OS and IDFS rates with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Most women with breast cancer who paused endocrine ...

Norman Parathyroid Center, Clayman Thyroid Center, and Carling Adrenal Center Expand Their Lead as the World’s ...